amiodarone has been researched along with Ventricular Dysfunction in 8 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Ventricular Dysfunction: A condition in which HEART VENTRICLES exhibit impaired function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to assess the association of amiodarone use with mortality during consecutive periods in patients with post-acute myocardial infarction with left ventricular systolic dysfunction and/or HF treated with a contemporary medical regimen." | 9.13 | Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. ( Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ, 2008) |
| "Fetuses with incessant tachycardia and either hydrops fetalis (n=24) or ventricular dysfunction (n=2) for whom digoxin monotherapy and secondary antiarrhythmic agents (n=13) were not effective were treated transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followed by daily maintenance therapy for <1 to 15 weeks." | 7.72 | Amiodarone therapy for drug-refractory fetal tachycardia. ( Cuneo, BF; Deal, BJ; Feinkind, L; Gotteiner, NL; Hussey, M; McGregor, SN; Meijboom, EJ; Michon, MM; Oudijk, MA; Parilla, BV; Strasburger, JF, 2004) |
| "We sought to assess the association of amiodarone use with mortality during consecutive periods in patients with post-acute myocardial infarction with left ventricular systolic dysfunction and/or HF treated with a contemporary medical regimen." | 5.13 | Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. ( Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ, 2008) |
| "The European Myocardial Infarct Amiodarone Trial (EMIAT) investigated the effects of amiodarone versus placebo in patients after myocardial infarction who had left ventricular ejection fraction | 3.73 | Usefulness of ventricular repolarization dynamicity in predicting arrhythmic deaths in patients with ischemic cardiomyopathy (from the European Myocardial Infarct Amiodarone Trial). ( Badilini, F; Benchetrit, C; Coumel, P; Leenhardt, A; Maisonblanche, P; Milliez, P; Siliste, C; Vicaut, E, 2005) |
| "Fetuses with incessant tachycardia and either hydrops fetalis (n=24) or ventricular dysfunction (n=2) for whom digoxin monotherapy and secondary antiarrhythmic agents (n=13) were not effective were treated transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followed by daily maintenance therapy for <1 to 15 weeks." | 3.72 | Amiodarone therapy for drug-refractory fetal tachycardia. ( Cuneo, BF; Deal, BJ; Feinkind, L; Gotteiner, NL; Hussey, M; McGregor, SN; Meijboom, EJ; Michon, MM; Oudijk, MA; Parilla, BV; Strasburger, JF, 2004) |
| "The general principles of management of congestive heart failure encompass patient evaluation and confirmation of the diagnosis, consideration, and correction of underlying remediable causes and precipitating factors, pharmacological treatment, patient education and counseling, and planned follow-up, as summarized in recently published guidelines." | 2.40 | Symptomatic systolic ventricular failure. ( Sharpe, N, 1999) |
| "Carvedilol is an effective additional therapy for the patients with chronic heart failure already receiving Amiodarone." | 1.46 | THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS. ( Khintibidze, I; Tsetskhladze, E, 2017) |
| "Knowledge on ventricular tachycardia (VT) in isolated ventricular noncompaction (IVNC) is limited." | 1.36 | Septal ventricular tachycardia with alternating LBBB-RBBB morphology in isolated ventricular noncompaction. ( Bulková, V; Fiala, M; Januska, J; Pleva, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsetskhladze, E | 1 |
| Khintibidze, I | 1 |
| Fiala, M | 1 |
| Januska, J | 1 |
| Bulková, V | 1 |
| Pleva, M | 1 |
| Strasburger, JF | 1 |
| Cuneo, BF | 1 |
| Michon, MM | 1 |
| Gotteiner, NL | 1 |
| Deal, BJ | 1 |
| McGregor, SN | 1 |
| Oudijk, MA | 1 |
| Meijboom, EJ | 1 |
| Feinkind, L | 1 |
| Hussey, M | 1 |
| Parilla, BV | 1 |
| Milliez, P | 1 |
| Leenhardt, A | 1 |
| Maisonblanche, P | 1 |
| Vicaut, E | 1 |
| Badilini, F | 1 |
| Siliste, C | 1 |
| Benchetrit, C | 1 |
| Coumel, P | 1 |
| Olesin, AI | 1 |
| Shabrov, AV | 1 |
| Sinenko, VI | 1 |
| Popik, GS | 1 |
| Boldueva, SA | 1 |
| Leonova, IA | 1 |
| Poloskina, OA | 1 |
| Satomi, K | 1 |
| Kurita, T | 1 |
| Takatsuki, S | 1 |
| Yokoyama, Y | 1 |
| Chinushi, M | 1 |
| Tsuboi, N | 1 |
| Nitta, T | 1 |
| Shoda, M | 1 |
| Mitamura, H | 1 |
| Thomas, KL | 1 |
| Al-Khatib, SM | 1 |
| Lokhnygina, Y | 1 |
| Solomon, SD | 1 |
| Kober, L | 1 |
| McMurray, JJ | 1 |
| Califf, RM | 1 |
| Velazquez, EJ | 1 |
| Sharpe, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amiodarone and Ventricular Dysfunction
| Article | Year |
|---|---|
Symptomatic systolic ventricular failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel B | 1999 |
1 trial available for amiodarone and Ventricular Dysfunction
| Article | Year |
|---|---|
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; | 2008 |
6 other studies available for amiodarone and Ventricular Dysfunction
| Article | Year |
|---|---|
THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2017 |
Septal ventricular tachycardia with alternating LBBB-RBBB morphology in isolated ventricular noncompaction.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Bundle-Branch Block; Catheter Ablation; Echocardiogr | 2010 |
Amiodarone therapy for drug-refractory fetal tachycardia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Electrocardiography; Female; Fetal Dise | 2004 |
Usefulness of ventricular repolarization dynamicity in predicting arrhythmic deaths in patients with ischemic cardiomyopathy (from the European Myocardial Infarct Amiodarone Trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Death; Electrocard | 2005 |
[Possibility of differentiated treatment of ventricular heart rate disturbances based on mechanism of their development].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol; Ventricular Dysfunction | 2005 |
Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia | 2006 |